EP0750670A1 - Compositions utiles pour traiter la maladie de marek - Google Patents
Compositions utiles pour traiter la maladie de marekInfo
- Publication number
- EP0750670A1 EP0750670A1 EP95909517A EP95909517A EP0750670A1 EP 0750670 A1 EP0750670 A1 EP 0750670A1 EP 95909517 A EP95909517 A EP 95909517A EP 95909517 A EP95909517 A EP 95909517A EP 0750670 A1 EP0750670 A1 EP 0750670A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mdv
- orf
- vaccine
- sequence
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000006758 Marek Disease Diseases 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims description 36
- 241000287828 Gallus gallus Species 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 10
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 230000002238 attenuated effect Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 244000144977 poultry Species 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 231100001222 nononcogenic Toxicity 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 4
- 241000700662 Fowlpox virus Species 0.000 claims description 3
- 229940031348 multivalent vaccine Drugs 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 abstract description 70
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 238000002255 vaccination Methods 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000011712 cell development Effects 0.000 abstract description 5
- 108700002232 Immediate-Early Genes Proteins 0.000 abstract description 2
- 230000002101 lytic effect Effects 0.000 abstract description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 53
- 235000013330 chicken meat Nutrition 0.000 description 30
- 239000002299 complementary DNA Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 239000012634 fragment Substances 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 238000000636 Northern blotting Methods 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 102000006382 Ribonucleases Human genes 0.000 description 7
- 108010083644 Ribonucleases Proteins 0.000 description 7
- 101150066555 lacZ gene Proteins 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108091034057 RNA (poly(A)) Proteins 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 101100024330 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSB1 gene Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- GGEJHJIXRBTJPD-BYPYZUCNSA-N Gly-Asn-Gly Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GGEJHJIXRBTJPD-BYPYZUCNSA-N 0.000 description 1
- AYUOWUNWZGTNKB-ULQDDVLXSA-N His-Phe-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AYUOWUNWZGTNKB-ULQDDVLXSA-N 0.000 description 1
- RLAOTFTXBFQJDV-KKUMJFAQSA-N His-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CN=CN1 RLAOTFTXBFQJDV-KKUMJFAQSA-N 0.000 description 1
- NBWATNYAUVSAEQ-ZEILLAHLSA-N His-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O NBWATNYAUVSAEQ-ZEILLAHLSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- JUJGNDZIKKQMDJ-IHRRRGAJSA-N Pro-His-His Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O JUJGNDZIKKQMDJ-IHRRRGAJSA-N 0.000 description 1
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 1
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- YXEYTHXDRDAIOJ-CWRNSKLLSA-N Ser-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N)C(=O)O YXEYTHXDRDAIOJ-CWRNSKLLSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- DDRBQONWVBDQOY-GUBZILKMSA-N Val-Ala-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DDRBQONWVBDQOY-GUBZILKMSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940031416 bivalent vaccine Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010019832 glycyl-asparaginyl-glycine Proteins 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000009837 laryngotracheitis Diseases 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 or alternatively Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a composition comprising a novel protein expressed by cells infected with Marek's disease virus (MDV) . More particularly, mechanisms of protection of chickens against Marek's disease are provided by using this novel protein as a vaccine antigen.
- MDV Marek's disease virus
- Marek's disease is a lymphoproliferative disease of chickens caused by MDV.
- MDV a naturally occurring herpesvirus, infects bursa-derived and thymus-derived lymphocytes in chickens, and can subsequently cause malignant T-cell lymphomas in chickens.
- the MDV genome is present in tumors induced in the MDV-infected chickens, these tumors are generally free of virus particles indicating that latency has been established.
- MDV-infected chickens may also exhibit neural involvement characterized by nerve paralysis. Since
- Marek's disease is contagious, the virus has become an important pathogen of chickens, particularly in an environment of large scale breeding such as in the poultry industry. Because of a lack of effective therapeutic drugs for treatment of Marek's disease, approaches to prevent the disease have focused on vaccine development.
- One such vaccine described in U.S. Patent No. 4,160,024, involves a strain of MDV which is naturally nononcogenic and unattenuated.
- Another vaccine disclosed in U.S.
- Patent No. 4,980,162 is a combined vaccine consisting of cultured cells infected with an attenuated infectious laryngotracheitis virus, and cultured cells infected with attenuated MDV or herpesvirus of turkey (HVT) .
- HVT herpesvirus of turkey
- Marek's disease is controlled by vaccination of embryos at 17-19 days of incubation, or one day old chicks with either HVT; serotype 2 strains of MDV; attenuated (of low pathogenicity) and/or nononcogenic strains of MDV serotype 1, or combinations thereof.
- HVT herniated virus
- MDV serotype 1 a bivalent vaccine consisting of serotype 2 MDV or HVT
- Increased virulence of MDV isolates, decreased genetic resistance of chicken stocks, immunosuppression by other microbial pathogens, and poor management of vaccination procedures may be factors which have contributed to recent vaccination breaks.
- a novel sequence comprising a small open reading frame (ORF) , has been identified in the MDV genome. RNA transcripts from this sequence have been detected in Marek's disease tumor cell lines, which have a limited number of MDV-specific transcripts. Also, transcription from this sequence occurs in lytically-infected cells.
- the novel sequence of the present invention may be non- essential for virus replication, and therefore may be used as a region for insertion and expression in MDV of other endogenous (MDV) genes or exogenous genes.
- one object of the present invention is to provide an approach to control MDV infection by preventing the development of Marek's disease through the induction of a protective antibody and/or a cell- mediated immune response to a protein which may be associated with lytic infection and/or tumor cell development of MDV-infected cells.
- Another object of the present invention is to provide a region in the MDV genome, wherein the region is non-essential for virus replication, into which an extra copy(s) of an endogenous (MDV) gene or exogenous gene can be inserted for expression from this recombinant viral vector.
- FIG. 1 is a schematic representation of the genomic structure of MDV with restriction map position of the BairiHI-A region, and the location of the BairiHI-A-specific cDNA clone A41.
- the A41 cDNA clone is shown as an open box, and the clone's open reading frame (ORF) encoding 94 amino acids is shown below as a line bar.
- ORF open reading frame
- AATAAA polyadenylation signal
- FIG. 2 represents Northern blot analyses to confirm the origins of the A41 cDNA clone. Sizes of transcripts are shown in kilobases.
- FIG. 2A represents a Northern blot using pol (A) + RNA isolated from either CU41 (lane 1) , or the negative control line CU91 (lane 2) , hybridized with a probe prepared from the A41 cDNA clone.
- FIG. 2B represents a Northern blot using total cellular RNA extracted from either uninfected chicken kidney cells (CKC) (lane 1) , or MDV strain RB1B-infected KC (lane 2) , hybridized with the same probe as used in FIG. 2A.
- FIG. 3 is a representation of the nucleotide sequence of the BairiHI-A-specific cDNA clone and its upstream genomic sequence obtained from analysis of the A41 clone.
- the predicted amino acid sequence of the ORF is shown by the single-letter code above the nucleotide sequence, with amino acid numbers in parentheses.
- the location of a potential polyadenylation sequence is underlined and indicated (AATAAA) .
- the locations of primers (#1 and #2) used to obtain the A41 clone, and restriction enzyme sites within the sequence are also underlined and indicated.
- FIG. 4 is a schematic representation showing the locations of the two probes used in the RNase protection assay.
- FIG. 5 represents RNase protection assays of total RNAs from RB1B-infected CKC and CU41.
- Lane 1 represents size markers (in bp) ;
- lane 2 represents each undigested full-length probe;
- lane 3 represents RNA from uninfected CKC;
- lane 4 represents RNA from uninfected CKC;
- lane 5 represents RNA from CU197;
- lane 6 represents RNA from RB1B-infected CKC; and
- lane 7 represents RNA from CU41.
- FIG. 5A represents the RNase protection assay using probe 1 in the hybridization to the RNAs.
- FIG. 5B represents the RNase protection assay using probe 2 in the hybridization to the RNAs.
- FIG. 6 represents a photograph of immunofluorescence staining of RB1B-infected CKC with chicken anti-A41 antibody.
- the MDV genome is a linear 180 kilobase pair double stranded molecule consisting of two unique regions: a unique short region (US) , and a unique long region (UL) . Each of the unique regions is flanked by inverted repeats: a long terminal repeat (TRL) and internal long inverted repeat (IRL) for UL, and a short internal inverted repeat (IRS) and short terminal repeat (TRS) for US ( Figure 1) .
- TRL long terminal repeat
- INL internal long inverted repeat
- RLS short internal inverted repeat
- TRS short terminal repeat
- the present invention relates to the identification and characterization of a MDV-specific cDNA clone, "A41", the sequence of which originates in the IRS region near the IRS-US junction as represented in Figure 1.
- the cDNA clone was isolated from a cDNA library prepared from a Marek's disease lymphoblastoid cell line, MDCC-CU41 (CU41) .
- CU41 is a non-expression cell line which contains none or only a few cells expressing viral antigens. However, A41 transcripts appear to be expressed in relatively higher amounts in lytically- infected cells (Fig. 2B, lane 2) than in the Marek's disease lymphoblastoid cell line CU41 (Fig. 2A, lane 1) .
- A41 ORF one open reading frame
- the A41 ORF, and its corresponding gene product of 94 amino acids may be associated with initiation and maintenance of tumor cell development and/or establishment of latency in MDV-infected cells.
- One embodiment of the present invention relates to vaccination with the 94 amino acid gene product of the A4l ORF.
- chicks or chickens are immunized with a vaccine comprising the 94 amino acid protein which may elicit protection by inducing an immune response that would recognize cells lytically-infected with MDV to prevent the development of latency or tumor cells subsequently induced by MDV infection.
- the vaccine comprises a vector, such as a recombinant viral vector, containing the A41 ORF under the control of a strong promoter so that the 94 amino acid protein is expressed.
- the vaccine comprises a vector such as a recombinant viral vector, containing those nucleotide sequences of this A41 ORF coding for epitopes inducing humoral (approximately 15 amino acids) or cell-mediated (approximately 9 amino acids) immune responses.
- a second embodiment is the development of a Marek's disease virus which lacks oncogenicity. As noted in U.S. Patent No. 4,160,024 to Schat et al..
- the A41 ORF of an unattenuated pathogenic strain of MDV can be genetically engineered not to express the 94 amino acid protein. Since the A41 ORF appears non-essential for virus replication, expression of the 94 amino acid protein can be interrupted by the insertion of an exogenous sequence into the A41 ORF, resulting in a recombinant MDV that may be unattenuated, apathogenic, and non-oncogenic.
- the recombinant MDV can be used as a vector in a multivalent vaccine by inserting one or more exogenous genes into the A41 ORF.
- An exogenous gene would encode protein which acts as an effective antigen in inducing a protective immune response against its corresponding organism of origin.
- the recombinant MDV could serve as a combined vaccine against Marek's disease and against other diseases of poultry.
- one or more copies of an endogenous gene, whose gene product is an antigen capable of eliciting a protective immune response can be inserted under the control of a strong constitutive promoter into the A41 ORF to increase antigen expression for vaccine purposes.
- glycoprotein B is a major glycoprotein produced by MDV, which when inoculated into chickens results in the production of neutralizing antibody.
- Multiple copies of the gene encoding gB can be inserted in the A41 ORF to make a more effective recombinant vaccine against Marek's disease.
- the A41 ORF is a sequence derived from the sequence of an MDV-specific cDNA clone, A41, obtained through screening of the CU41 cDNA library with the gel-purified BairiHI-A fragment as a probe.
- CU41 a Marek's disease lymphoblastoid cell line established from a RBIB-induced tumor (MDV strain RBIB is a very highly oncogenic strain described previously by Schat et al., 1982, Avian Pathol . 11:593-605), is a non-expression cell line which contains none or only a few cells expressing viral antigens (Calnek et al., 1981, Infect . Im un .
- CU41 was selected for making the cDNA library because only six MDV-specific transcripts, including 3.7, 1.7, 1.1 and 0.9-kb BairiHI-A transcripts, were detected in this cell line (Schat et al., 1989, supra) .
- a cDNA library was prepared from the poly(A) + RNA obtained from CU41 cells. The library was screened by plaque hybridization with a 32 P-labeled MDV (strain GA) BairiHI-A fragment, and the hybridizing phages were plaque-purified. Subsequent in vivo excision and rescue of pBluescript (SK)TM carrying cDNA inserts were performed.
- Southern blot analysis was performed to determine the approximate map position of the cDNA clone A41.
- the BairiHI-A fragment was digested by either Bgrll, Smal, Ec ⁇ RI, HindiII, or Xhol fractionated on 0.8% agarose gels, and transferred to nylon hybridization membranes. Southern blot analyses were performed using 32 P-labeled probes, prepared by using gel-purified cDNA inserts as templates, for hybridization with the membranes.
- Poly(A) + RNA purified from the total cellular RNA preparations, were used in the Northern blot analysis of CU41 and CU91.
- 2 ⁇ g of each of the poly(A) + RNA fractions were fractionated by electrophoresis in 1.2 % agarose gel containing 2.2 M formaldehyde (15), and blotted onto nylon membranes.
- RNA blots were prehybridized for 3 hours at 42° C in 50% ⁇ formamide, 5X SSPE, 5X Denhardt's solution, 0.1% SDS and 100 ⁇ g/ml denatured salmon sperm DNA. Hybridization was performed for 18-20 hours at 42°C in the same solution with addition of the radiolabeled A41 probe. After hybridization, the membranes were washed twice with 2X SSPE containing 0.5% SDS at 65°C for 60 minutes. The hybridized filters were autoradiographed at -80°C with Kodak X-Omat AR film and intensifying screens. The results of the Northern blot analysis of the poly(A) +
- RNA fractions from CU41 and CU91 are shown in Figure 2A.
- Total RNA extracted from lytically-infected cells were also used to confirm the presence of the transcripts found in CU41 using the A41 probe.
- the results of the Northern blot analysis of the total RNA fractions from uninfected chicken kidney cells (CKC) , and RBIB-infected CKCs, are shown in Figure 2B.
- Hybridization with the A41 probe resulted in the detection of major transcripts of 2.5 kb and 1.2 kb, and minor transcripts of 4.8 kb and 0.9 kb, in RBIB-infected CKC (Fig. 2B, lane 2) but no transcripts were detected in uninfected CKC (Fig. 2B, lane 1) .
- the amounts of these transcripts detected by Northern blot analyses using the A41 probe appear to be relatively more abundant in the RNA sample of RBIB-infected CKC than in that of CU41.
- a comparison of A41-specific RNA transcripts detected in CU41 and RBIB-infected CKC is shown in Table 1.
- RNase protection assays were performed using two different probes which covered the 5' portion of the A41 ORF and its upstream region, as shown in Figure 4. Two subclones, a 301 bp Bgrlll-Xhol fragment, and a 296 bp hol- ⁇ fscl fragment, were used as templates for synthesizing 32 P-labeled antisense RNA probes.
- RNA sample 50 ⁇ g
- CU197 a reticuloendotheliosis-transformed T lymphoblastoid cell line
- RBlB-infected CKC RBlB-infected CKC
- uninfected CKC uninfected CKC
- EXAMPLE 2 This embodiment of the present invention relates to vaccination with the 94 amino acid (aa) gene product of the A41 ORF.
- chicks or chickens are immunized with a vaccine comprising the 94 aa protein which may elicit protection by inducing an immune response that would recognize cells lytically- infected with MDV, or tumor cells induced by MDV infection.
- the 94 aa protein from infected cells, or recombinant protein produced from an expression vector system can be purified with methods known in the art including detergent extraction and/or immunoaffinity chromatography.
- Immunopurification of the protein from an expression vector system may be accomplished using methods known in the art for immunoaffinity chromatography including use of 94 aa protein-specific monoclonal antibodies linked to a chromatographic matrix to form an affinity matrix.
- a protein preparation is then incubated with the affinity matrix allowing the antibodies to bind to the 94 aa protein.
- the affinity matrix is then washed to remove unbound components and the 94 aa protein is then eluted from the affinity matrix resulting in a purified preparation of 94 aa protein.
- the purified 94 aa protein may be chemically or enzymatically cleaved into peptides, or alternatively, peptides may be synthesized using the deduced amino acid sequence from the A41 ORF (SEQ ID No. 1) as a reference. Peptides derived from the 94 aa protein may also be useful in a vaccine preparation.
- a substantial portion of the 94 aa protein has been purified using an expression system wherein the plasmid expression vector (pGEX2T) directs the synthesis of foreign polypeptides in Escherichia coli as a fusion protein with glutathione-S- ransferase (GST) , a 26 kilodalton protein from Schistosoma japonicum.
- GST glutathione-S- ransferase
- a 569 bp Mscl -Nrul fragment containing 92 of the 94 amino acids of the A41 ORF was recloned in frame into the 3'end of the GST ORF in pGEX- 2T.
- the resultant recombinant plasmid was designated pGEXA41SB.
- coli strain DH5 ⁇ were transformed either with pGEXA41SB, or pGEX2T as a negative control.
- the respective transformants were grown in 3 ml of LB broth with ampicillin at 37°C overnight. Then, the cultures were diluted x 100 in LB broth with ampicillin and incubated for 2 hours at 37°C with shaking. IPTG was added to 2mM and the cultures were incubated for an additional 3 hours. After IPTG induction, the cells were harvested by centrifugation and the fusion protein and GST were purified by affinity chromatography with a glutathione-containing column matrix. Fractions containing the fusion protein were further purified by SDS-PAGE and subsequent electroelution. The purified recombinant protein termed GST A41, and the control protein GST were dialyzed against PBS for at least 24 hours at 4°.
- Specific pathogen-free line P-2a chickens were injected subcutaneously with either GST A41 or GST in an adjuvant. Four weeks after this first immunization, the chickens were injected intravenously with the respective protein without adjuvant.
- the polyclonal antisera, anti-GST A41 and anti-GST were used in indirect immunofluorescent antibody assays of CU41, RBIB-infected CKC and MSB1 (an expression Marek's disease cell line) . Acetonefixed cells were incubated with antisera against the fusion proteins for 30 minutes at room temperature and then washed twice with phosphate-bufered saline (PBS, pH 7.4) for 10 minutes.
- PBS phosphate-bufered saline
- the washed cells were then incubated with fluorescein isothiocyanate (FITC) - conjugated rabbit anti-chicken IgG for 30 minutes at room temperature.
- FITC fluorescein isothiocyanate
- Cells were examined with a fluorescence microscope after three 5-minute washes with PBS.
- MSB1 cells were double-stained with anti-GST A41 antibody, and a monoclonal antibody that recognizes MDV- specific phosphoprotems.
- FITC-conjugated rabbit anti- chicken IgG, and trimethylrhodamine isothiocyanate- conjugated rabbit anti-mouse IgG were used as secondary antibodies. Immunoperoxidase staining of the various cells was also performed. Goat anti-chicken antiserum labeled with peroxidase was used as a secondary reagent in this experiment.
- An expression vector system useful for vaccine development, comprises a host containing a recombinant vector which expresses the 94 aa protein, or a peptide thereof containing immunogenic epitopes.
- Such hosts include, but are not limited to, bacterial transformants, yeast transformants, filamentous fungal transformants, and cultured cells that have been either infected or transfected with a vector which encodes the 94 aa protein.
- the protein or peptide immunogen is included in a vaccine formulation in pharmacologically effective amounts to induce an immune response.
- the vaccine may further comprise a physiological carrier such as a solution, a polymer or liposomes; and an adjuvant, or a combination thereof.
- Another mode of this embodiment provides for either a live recombinant viral vaccine, or an inactivated recombinant viral vaccine, comprising a viral vector containing the A41 ORF under the control of a strong promoter so that the 94 amino acid protein is expressed.
- viral vectors known in the art include a live attenuated infectious laryngotracheitis virus, attenuated chick fowlpox virus, or attenuated herpes virus of turkey; i.e. an infectious virus that can be engineered to express vaccine antigens derived from other organisms.
- the recombinant live virus which is attenuated or otherwise treated so that it does not cause disease by itself, is used to immunize chicks or chickens. Subsequent replication of the recombinant virus within the host provides a continual stimulation of the immune system with vaccine antigens such as the 94 aa protein, thereby providing long-lasting immunity.
- the A41 ORF may be inserted into the viral vector genomic DNA at a site which allows for expression of the 94 aa protein epitopes but does not negatively affect the growth or replication of the viral vector.
- the resultant recombinant virus can be used as the immunogen in a vaccine formulation.
- the same methods can be used to construct an inactivated recombinant viral vaccine formulation except that the recombinant virus is inactivated, such as by chemical means known in the art, prior to use as an immunogen.
- the DNA comprising the expression vector containing the A41 ORF such as for example a recombinant viral vector, can be used in a subunit vaccine.
- Gene vaccines comprising antigen encoding DNAs have been described in the art. Direct gene transfer into animals resulting in expression of the exogenous gene in vascular endothelial cells, as well as the tissue of major organs, has been demonstrated by techniques such as injecting intravenously an expression plasmid:cationic liposome complex (Zhu et al., 1993, Science 261:209) . Other effective methods for delivering vector DNA into a target cell are known in the art. In one example, purified recombinant plasmid DNA containing viral genes has been used to inoculate (whether parentally, mucosally, or via gene-gun immunization) chickens to induce a protective immune response (Fynan et al., 1993, Proc.
- cells removed from the chick or embryo can be transfected or electroporated by standard procedures known in the art, resulting in the introduction of the vector DNA into the target cell.
- Cells containing the vector DNA may be selected from those lacking the vector DNA by incorporating a selection marker into the vector such as the neo gene, and growing the cells in the corresponding selection media such as in the presence of G418.
- Selected cells, containing the recombinant expression vector for expressing the 94 aa protein or peptides derived therefrom, may then be reintroduced into the chick or embryo.
- EXAMPLE 3 This embodiment of the present invention provides for the development of a Marek's disease virus which may lack oncogenicity.
- unattenuated pathogenic strains of MDV have been unacceptable as vaccines for poultry because of their oncogenic potential.
- the A41 ORF of an unattenuated pathogenic strain of MDV can be genetically engineered not to express the 94 amino acid protein by inserting an exogenous sequence into the A41 ORF to interrupt its expression.
- the US/IRS junction region from which the A41 clone originates has been deleted in a MDV strain JM clone isolated and characterized recently (Kost et al.
- the A41 ORF is non-essential for virus replication in vitro. It is believed that the immediate early genes, such as the A41 ORF, play an essential role in the initiation and/or maintenance of transformation by MDV.
- the immediate early genes such as the A41 ORF
- a recombinant MDV that is unattenuated, pathogenic, and non-oncogenic may be developed which would be useful in a vaccine against MDV.
- the recombinant viral DNA may be used in the vaccine composition as described according to Example 2.
- MDV can be used as a vector in a multivalent vaccine by inserting one or more exogenous genes, under the control of its own promoter or a MDV promoter, into the A41 ORF.
- a deletion into the A41 ORF results in a MDV clone still capable of replicating in chicken cells in vi tro, thus it is likely that interruption of the A41 ORF by an insertion would result in a clone of similar capabilities.
- Successful insertion of the lacZ ORF into the A41 ORF is further evidence that the A41 ORF can serve as a site in the MDV genome for insertion of exogenous genes. This was accomplished by inserting a lacZ cassette containing the SV40 promoter into a A41 ORF-containing plasmid.
- the final resulting plasmid contained the lacZ in forward orientation inserted in the remaining sequence of the A41 ORF.
- Total MDV DNA was purified from the CV1988 strain of MDV.
- MDV fragments containing lacZ were prepared by restriction enzyme digestion of the plasmid containing the lacZ cassette inserted into the A41 ORF.
- Total MDV DNA and MDV fragments containing lacZ were used to co-transfect chicken embryo fibroblasts (CEF) using the calcium precipitation method. Cultures were stained with 0.2 mg/ml Bluo-GalTM at 5 days post transfection; and blue staining plaques were removed from the monolayer, trypsinized, and co-cultured with secondary CEF.
- Recombinant viruses were plaque-purified by repeating selection of lacZ-expressing plaques (usually 4-6 times) until stable recombinants were isolated.
- Chicken embryo fibroblasts have been lytically-infected with the plaque-purified lacZ- expressing recombinant MDV, thus demonstrating that the A41 ORF is non-essential for virus replication, and can be used as an insertion site for the expression of exogenous genes.
- one or more exogenous gene(s) inserted into the A41 ORF would encode protein which acts as an effective antigen in inducing a protective immune response against its corresponding organism of origin.
- the recombinant MDV could serve as a combined vaccine against Marek's disease and against other diseases of poultry.
- antigens useful in a combined vaccine, and their corresponding pathogen and disease caused are known in the art of veterinary medicine.
- genes encoding antigens of infectious laryngotracheitis virus causing infectious laryngotracheitis can be inserted into the A41 ORF for expression.
- one or more copies of the gene encoding the viral hemagglutinin glycoprotein of the chicken fowlpox virus causing fowlpox can be inserted into the A41 ORF for expression.
- one or more copies of either or both of the gene encoding the HN antigen or the gene encoding the F antigen of Newcastle disease virus causing Newcastle disease can be inserted in the A41 ORF for expression. Recombinant expression of Newcastle disease viral antigens in HVT has been described previously (Morgan et al. in Proceedings XIX World's Poultry Congress. Amsterdam, The Netherlands, 1993) .
- one or more copies of an endogenous (MDV) gene can be inserted within the A41 ORF to increase antigen expression for vaccine purposes.
- MDV endogenous
- glycoprotein B gB
- MDV glycoprotein B
- Multiple copies of the gene encoding gB can be inserted in the A41 ORF under the control of a MDV promoter to make a more effective recombinant vaccine against Marek's disease.
- One or more of the other major viral glycoproteins of MDV, such as gA may induce a protective immune response consisting of either cellular immunity, or humoral immunity.
- ORGANISM Marek's Disease Virus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19263394A | 1994-02-07 | 1994-02-07 | |
US192633 | 1994-02-07 | ||
PCT/US1995/001615 WO1995021255A1 (fr) | 1994-02-07 | 1995-02-06 | Compositions utiles pour traiter la maladie de marek |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0750670A1 true EP0750670A1 (fr) | 1997-01-02 |
EP0750670A4 EP0750670A4 (fr) | 1997-01-15 |
Family
ID=22710445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95909517A Withdrawn EP0750670A1 (fr) | 1994-02-07 | 1995-02-06 | Compositions utiles pour traiter la maladie de marek |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0750670A1 (fr) |
WO (1) | WO1995021255A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470160B (zh) * | 2022-03-18 | 2023-08-25 | 山东农业大学 | 病毒复制抑制剂及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002802A2 (fr) * | 1988-09-13 | 1990-03-22 | Institute For Animal Health Limited | Sequences de nucleotides virales |
EP0473210A2 (fr) * | 1990-07-30 | 1992-03-04 | Akzo Nobel N.V. | Virus recombinant de la maladie de Marek |
EP0513921A2 (fr) * | 1991-05-14 | 1992-11-19 | Akzo Nobel N.V. | Vaccin recombinant contre la maladie de Marek |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69016956T2 (de) * | 1989-12-04 | 1995-07-20 | Akzo Nobel Nv | Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor. |
AU657144B2 (en) * | 1991-07-09 | 1995-03-02 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same |
-
1995
- 1995-02-06 EP EP95909517A patent/EP0750670A1/fr not_active Withdrawn
- 1995-02-06 WO PCT/US1995/001615 patent/WO1995021255A1/fr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002802A2 (fr) * | 1988-09-13 | 1990-03-22 | Institute For Animal Health Limited | Sequences de nucleotides virales |
EP0473210A2 (fr) * | 1990-07-30 | 1992-03-04 | Akzo Nobel N.V. | Virus recombinant de la maladie de Marek |
EP0513921A2 (fr) * | 1991-05-14 | 1992-11-19 | Akzo Nobel N.V. | Vaccin recombinant contre la maladie de Marek |
Non-Patent Citations (1)
Title |
---|
See also references of WO9521255A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0750670A4 (fr) | 1997-01-15 |
WO1995021255A1 (fr) | 1995-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2031164C (fr) | Herpesvirus recombinant de dindons et vaccins de vecteur vivant qui en sont derives | |
Gong et al. | Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB | |
AT400724B (de) | Virales polypeptid | |
Coussens et al. | Structure and complete nucleotide sequence of the Marek's disease herpesvirus gp57-65 gene | |
JP2002176992A (ja) | Hcmvの糖タンパク質 | |
IE913711A1 (en) | Baculoviral expression system comprising procaryotic leader sequence | |
JP3829290B2 (ja) | ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途 | |
AU629381B2 (en) | Feline calicivirus capsid protein and nucleotide sequence | |
US5283191A (en) | Mareks' disease virus vaccine | |
CA2086739A1 (fr) | Vaccin a base de glycoproteines contre le ehv-4 | |
EP0513921B1 (fr) | Vaccin recombinant contre la maladie de Marek | |
US5718901A (en) | Feline calicivirus gene | |
JP3964458B2 (ja) | 組換え型伝染性喉頭気管炎ウイルスおよびその使用 | |
US5789567A (en) | Chicken infectious anemia virus vaccine | |
EP0423869B1 (fr) | Vaccin contre le virus de la bronchite infectieuse (IBV) | |
WO1995021255A1 (fr) | Compositions utiles pour traiter la maladie de marek | |
WO1995021255A9 (fr) | Compositions utiles pour traiter la maladie de marek | |
WO1996001116A9 (fr) | Vaccin contre le virus de l'anemie infectieuse du poulet | |
US7348422B2 (en) | Fused protein, gene therefor, recombinant vector, recombinant virus, and its use | |
EP0745127A1 (fr) | Controle de la maladie de marek par inhibition de la latence et du developpement des cellules tumorales | |
JPH09505726A (ja) | 組換え感染性喉頭気管炎ウイルス及びそれらの使用 | |
JANG et al. | Marek's disease virus serotype 2 glycoprotein I gene: nucleotide sequence and expression by a recombinant baculovirus | |
JP3428666B2 (ja) | 組換えマレック病ウイルスおよびその製法 | |
US5690939A (en) | Recombinant vaccine against marek's disease | |
JP2002515248A (ja) | 出血性腸炎ウイルスのdna配列、それによりコードされるタンパク質およびその様々な用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960821 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19961126 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19980901 |